scholarly journals SURGICAL TREATMENT OF CERVICAL STENOSIS IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS: SYSTEMATIC REVIEW

2018 ◽  
Vol 24 (2) ◽  
pp. 127-137
Author(s):  
S. V. Kolesov ◽  
L. K. Mikhaylova ◽  
D. A. Kolbovsky ◽  
V. S. Pereverzev

A multidisciplinary approach to treatment of patients with mucopolysaccharidosis allows to achieve good results. However, progressive spinal canal stenosis at the level of the craniovertebral junction, characteristic of this disease, leads to neurological signs, as well as a decrease in quality and length of life. The solution to this problem is a difficult challenge for spinal surgeons, as it is associated with a high risk of complications. There is also a wide range of opinions and approaches to the surgical treatment of this group of patients.Using the referred Reporting Items for Systematic Review and Meta-Analysis» (PRISMA) protocol, a PubMed and eLIBRARY search was conducted using keywords to find articles describing patients with mucopolysaccharidosis who underwent surgical treatment for cervical stenosis. In this review, information on demographic parameters, surgical technique and the results of cervical stenosis treatment in patients with mucopolysaccharidosis is collected and analyzed.

Author(s):  
Kai Wei Lee ◽  
Sook Fan Yap ◽  
Yun Fong Ngeow ◽  
Munn Sann Lye

COVID-19 is a global health emergency. People living with human immunodeficiency virus (PLHIV) have concerns about whether they have a higher risk of getting the infection and suffer worse COVID-19 outcomes. Findings from studies on these questions have largely been inconsistent. We aimed to determine the epidemiological characteristics, clinical signs and symptoms, blood parameters, and clinical outcomes among PLHIV who contracted COVID-19. Relevant studies were identified through Medline, Cinahl, and PubMed databases. A random-effects model was used in meta-analyses with a 95% confidence interval. Eighty-two studies were included in the systematic review and sixty-seven studies for the meta-analysis. The pooled incidence proportion of COVID-19 among PLHIV was 0.9% (95% CI 0.6%, 1.1%) based on the data from seven cohort studies. Overall, 28.4% were hospitalised, of whom, 2.5% was severe-critical cases and 3.5% needed intensive care. The overall mortality rate was 5.3%. Hypertension was the most commonly reported comorbidity (24.0%). Fever (71.1%) was the most common symptom. Chest imaging demonstrated a wide range of abnormal findings encompassing common changes such as ground glass opacities and consolidation as well as a spectrum of less common abnormalities. Laboratory testing of inflammation markers showed that C-reactive protein, ferritin, and interleukin-6 were frequently elevated, albeit to different extents. Clinical features as well as the results of chest imaging and laboratory testing were similar in highly active antiretroviral therapy (HAART)-treated and non-treated patients. PLHIV were not found to be at higher risk for adverse outcomes of COVID-19. Hence, in COVID-19 management, it appears that they can be treated the same way as HIV negative individuals. Nevertheless, as the pandemic situation is rapidly evolving, more evidence may be needed to arrive at definitive recommendations.


2018 ◽  
Vol 55 (3) ◽  
pp. 296-305 ◽  
Author(s):  
Martin Andrés CORONEL ◽  
Wanderley Marques BERNARDO ◽  
Diogo Turiani Hourneaux de MOURA ◽  
Eduardo Turiani Hourneaux de MOURA ◽  
Igor Braga RIBEIRO ◽  
...  

ABSTRACT BACKGROUND: Endoscopic antireflux treatments for gastroesophageal reflux disease (GERD) are still evolving, and most of the published studies address symptom relief in the short-term. Objective - We aimed to perform a systematic review and meta-analysis focused on evaluating the efficacy of the different endoscopic procedures. METHODS: Search was restricted to randomized controlled trials (RCTs) on MedLine, Cochrane, SciELO, and EMBASE for patients with chronic GERD (>6 months), over 18 years old and available follow up of at least 3 months. The main outcome was to evaluate the efficacy of the different endoscopic treatments compared to sham, pharmacological or surgical treatment. Efficacy was measured by different subjective and objective outcomes. RESULTS: We analyzed data from 16 RCT, totaling 1085 patients. The efficacy of endoscopic treatments compared to sham and proton pump inhibitors (PPIs) treatment showed a significant difference up to 6 months in favor of endoscopy with no heterogeneity (P<0.00001) (I2: 0%). The subgroup analysis showed a statistically significant difference up to 6 months in favor of endoscopy: endoscopy vs PPI (P<0.00001) (I2: 39%). Endoscopy vs sham (P<0.00001) (I2: 0%). Most subjective and objective outcomes were statistically significant in favor of endoscopy up to 6 and 12 months follow up. CONCLUSION: This systematic review and meta-analysis shows a good short-term efficacy in favor of endoscopic procedures when comparing them to a sham and pharmacological or surgical treatment. Data on long-term follow up is lacking and this should be explored in future studies.


2017 ◽  
Vol 28 (11) ◽  
pp. 1761-1761 ◽  
Author(s):  
Shveta Kapoor ◽  
Kanapathippillai Sivanesan ◽  
Vishal Kapoor ◽  
Mayooran Veerasingham

CRANIO® ◽  
2022 ◽  
pp. 1-13
Author(s):  
Mário Serra Ferreira ◽  
Geovane Miranda ◽  
Fabiana T. Almeida ◽  
Giovanni Gasperini ◽  
Brunno Santos de Freitas Silva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document